Lead Product(s) : Cabergoline
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cabergoline vs Bromocriptine Mesylate Tablets in Clinical Study
Details : Cabergoline is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hyperprolactinemia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2025
Lead Product(s) : Cabergoline
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cabergoline
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study on Bioequivalence of Cabergoline Tablets in Human Body
Details : Cabergoline is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hyperprolactinemia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2025
Lead Product(s) : Cabergoline
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cabergoline
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cabergoline Before or After Oocyte Collection for Follicular Resolution
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2019
Lead Product(s) : Cabergoline
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
